Neutrolis Announces Positive First-in-Human Phase 1a Results from LIBERATE-I Trial of NTR-1011, a First-in-Class DNASE1L3 Fusion Protein

AI Briefing

• – Neutrolis announces positive Phase 1a results for NTR-1011, a treatment for autoimmune diseases.
• – The LIBERATE-I trial evaluated NTR-1011's ability to dismantle pathogenic NETs.
• – The company aims to develop rapid-acting, non-immunosuppressive therapies targeting NETs.